e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Macrolide resistance in
Pseudomonas aeruginosa
: implications for practice
James D. Chalmers
Source:
Eur Respir J, 49 (5) 1700689; 10.1183/13993003.00689-2017
Journal Issue:
May
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
James D. Chalmers. Macrolide resistance in
Pseudomonas aeruginosa
: implications for practice. Eur Respir J, 49 (5) 1700689; 10.1183/13993003.00689-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Definition and history of sarcoidosis
Related content which might interest you:
Characterization of the resistance mechanisms to carbapenems and virulence genes in Pseudomonas aeruginosa strains from children with cystic fibrosis.
Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects
Year: 2021
The impact of testosterone on Pseudomonas aeruginosa pathogenicity and antimicrobial susceptibility
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018
The role of efflux pump systems and OprD porine in antimicrobial resistance of Pseudomonas aeruginosa strains isolated from patients with bronchiectasis
Source: Virtual Congress 2021 – Back to infection basics
Year: 2021
Acquired resistance to macrolides in
Pseudomonas aeruginosa
from cystic fibrosis patients
Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016
Year: 2017
Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty?
Source: Eur Respir J 2010; 35: 473-474
Year: 2010
PES (Pseudomonas , Enterobacteriaceae S. Aureus MR) a new clinical acronym to identify MDR pneumonias in the community
Source: International Congress 2014 – Multidrug-resistant (MDR) pathogens that cause pneumonia
Year: 2014
Exploring the susceptibility of P. aeruginosa biofilms in human mucus towards tobramycin treatment
Source: International Congress 2017 – Cystic fibrosis: clinical issues
Year: 2017
Uncommon accumulation of multidrug resistance and virulence potential in carbapenemase ST-14 KPC-3 Klebsiella pneumoniae in Portugal: a high risk threat
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
Mechanisms of acquisition of resistance in
Staphylococcus aureus
Source: Annual Congress 2006 - Methicillin resistant
Staphylococcus aureus
(MRSA): a real hospital-based pathogen?
Year: 2006
Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis
Source: Virtual Congress 2021 – Back to infection basics
Year: 2021
CusS-cusR mediate carbapenem-resistant Klebsiella pneumoniae resistant to tigecycline.
Source: International Congress 2019 – Clinical challenges in respiratory infection
Year: 2019
Can transmissible strains of Pseudomonas aeruginosa be successfully eradicated?
Source: Eur Respir J 2011; 38: 1483-1486
Year: 2011
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis
Source: Eur Respir J , 49 (4) 1600851; DOI: 10.1183/13993003.00851-2016
Year: 2017
Host response to transmissible Pseudomonas aeruginosa
Source: Eur Respir J 2004; 23: 493-494
Year: 2004
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012
Treatment challenges in methicillin resistant
Staphylococcus aureus
infections
Source: Annual Congress 2006 - Methicillin resistant
Staphylococcus aureus
(MRSA): a real hospital-based pathogen?
Year: 2006
Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD.
Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond
Year: 2020
Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro
Source: Eur Respir J 2003; 21: 401-406
Year: 2003
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors
Source: Eur Respir J 2010; 35: 598-615
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept